gemfibrozil has been researched along with Atherogenesis in 10 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "Furthermore, hypertriglyceridemia is now recognized as an independent risk factor for coronary artery disease." | 2.43 | Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. ( Duriez, P; Fruchart, JC, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (90.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Fruchart, JC | 2 |
| Santos, RD | 1 |
| Rembold, CM | 1 |
| Lewis, SJ | 1 |
| Rosenson, RS | 1 |
| Calkin, AC | 2 |
| Cooper, ME | 1 |
| Jandeleit-Dahm, KA | 2 |
| Allen, TJ | 2 |
| Duriez, P | 1 |
| Lassila, M | 1 |
| Tikellis, C | 1 |
| Thomas, MC | 1 |
| Guzik, TJ | 1 |
| Harrison, DG | 1 |
| Bouhlel, MA | 1 |
| Staels, B | 1 |
| Chinetti-Gbaguidi, G | 1 |
| Brinton, EA | 1 |
5 reviews available for gemfibrozil and Atherogenesis
| Article | Year |
|---|---|
SPPARM alpha: the Lazarus effect.
Topics: Animals; Atherosclerosis; Benzoxazoles; Butyrates; Diabetes Mellitus, Type 2; Dyslipidemias; Fenofib | 2019 |
Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Gemfibrozil; Humans; Hypoli | 2005 |
Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
Topics: Animals; Anticholesteremic Agents; Atherosclerosis; Bezafibrate; Biological Transport; Cholesterol, | 2006 |
Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol; Clinical Trials as Topic; Fenofibrate; Gemfib | 2008 |
Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?
Topics: Atherosclerosis; Cardiovascular Diseases; Cholesterol, HDL; Clofibric Acid; Diabetic Angiopathies; D | 2008 |
5 other studies available for gemfibrozil and Atherogenesis
| Article | Year |
|---|---|
To statin or to non-statin in coronary disease-considering absolute risk is the answer.
Topics: Acute Coronary Syndrome; Atherosclerosis; Cholesterol, LDL; Coronary Artery Disease; Diet; Fatty Aci | 2008 |
Prevention and treatment of atherosclerosis: a practitioner's guide for 2008.
Topics: Anticholesteremic Agents; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Eicosapentaenoic Acid | 2009 |
Gemfibrozil decreases atherosclerosis in experimental diabetes in association with a reduction in oxidative stress and inflammation.
Topics: Angiotensins; Animals; Apolipoproteins E; Atherosclerosis; Biomarkers; Diabetes Mellitus, Experiment | 2006 |
Increased atherosclerosis following treatment with a dual PPAR agonist in the ApoE knockout mouse.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cardiovascular Diseases; Cell Adhesion; | 2007 |
Endothelial NF-kappaB as a mediator of kidney damage: the missing link between systemic vascular and renal disease?
Topics: Albuminuria; Angiotensin II; Animals; Atherosclerosis; Endothelium, Vascular; Fibrosis; Gemfibrozil; | 2007 |